| Dr Samuel Theodore Lee, MD | |
|
2845 Greenbrier Rd, Green Bay, WI 54311-6519 | |
| (920) 288-8000 | |
| Not Available |
| Full Name | Dr Samuel Theodore Lee |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 2845 Greenbrier Rd, Green Bay, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184989436 | NPI | - | NPPES |
| 100203539 | Medicaid | WI |
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
The association between regular aspirin use and a reduced risk of precancerous colon polyps may be strongest in those with particular genetic variants.
New research from The University of Texas Health Science Center at San Antonio and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment.
Knocking genes out of action allows researchers to learn what genes do by seeing what goes wrong without them. University of Utah biologists pioneered the field. Mario Capecchi won a Nobel Prize for developing knockout mice. Kent Golic found a way to cripple fruit fly genes. Now, biologist Erik Jorgensen and colleagues have devised a procedure for knocking out genes in nematode worms.
› Verified 7 days ago
| Entity Name | Baycare Aurora Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255387726 PECOS PAC ID: 0244130557 Enrollment ID: O20051012000579 |
News Archive
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
The association between regular aspirin use and a reduced risk of precancerous colon polyps may be strongest in those with particular genetic variants.
New research from The University of Texas Health Science Center at San Antonio and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment.
Knocking genes out of action allows researchers to learn what genes do by seeing what goes wrong without them. University of Utah biologists pioneered the field. Mario Capecchi won a Nobel Prize for developing knockout mice. Kent Golic found a way to cripple fruit fly genes. Now, biologist Erik Jorgensen and colleagues have devised a procedure for knocking out genes in nematode worms.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Samuel Theodore Lee, MD 3301 W Forest Home Ave, Milwaukee, WI 53215-2843 Ph: () - | Dr Samuel Theodore Lee, MD 2845 Greenbrier Rd, Green Bay, WI 54311-6519 Ph: (920) 288-8000 |
News Archive
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.
The association between regular aspirin use and a reduced risk of precancerous colon polyps may be strongest in those with particular genetic variants.
New research from The University of Texas Health Science Center at San Antonio and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment.
Knocking genes out of action allows researchers to learn what genes do by seeing what goes wrong without them. University of Utah biologists pioneered the field. Mario Capecchi won a Nobel Prize for developing knockout mice. Kent Golic found a way to cripple fruit fly genes. Now, biologist Erik Jorgensen and colleagues have devised a procedure for knocking out genes in nematode worms.
› Verified 7 days ago
Mary Lynn Bartel, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 835 S Van Buren St, Room 1041, Green Bay, WI 54301 Phone: 920-496-4700 Fax: 920-496-4705 | |
Kathleen Marie Barkow, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1821 S Webster Ave, Green Bay, WI 54301 Phone: 920-496-4700 Fax: 920-436-1319 | |
Kristina Ann Houn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2793 Lineville Rd, Green Bay, WI 54313 Phone: 920-496-4700 | |
George E Whetmore, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1821 S Webster Ave, Green Bay, WI 54301 Phone: 920-496-4700 Fax: 920-436-1319 | |
Ralph Joseph Vardis, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 835 S Van Buren St, Green Bay, WI 54301 Phone: 920-496-4700 Fax: 920-433-8569 | |
Dr. Robert Michael Rock Jr., MD Pediatrics Medicare: Medicare Enrolled Practice Location: 835 S. Vanburen St., Green Bay, WI 54301 Phone: 920-433-8360 Fax: 920-431-3163 | |
James F Winston, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 835 S Van Buren St, Green Bay, WI 54301 Phone: 920-433-8360 |